Market news

Armata Pharmaceuticals technical headwinds overshadow a $3.7 million Department of Defense grant funding its Phase 3 bacteriophage program.

Detailed price information for Rxsight Inc (RXST-Q) from The Globe and Mail including charting and trades.

Armata Pharmaceuticals (AMEX:ARMP) shares rose 8% after the company said the US Food and Drug Administration granted Breakthrough Therapy designation to AP-SA02, its intravenously administered Staphylococcus aureus multi-phage product candidate. The designation covers AP-SA02 as an adjunct treatment for complicated bacteremia caused by methicillin-sensitive S.

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity and potency, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the U.S. Food and Drug Administration (the "FDA") has granted Breakthrough Therapy designation to AP-SA02, the Company's intravenously administered Staphylococcus aureu

--Armata Pharmaceuticals, Inc., a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Deborah Birx, M.D., Chief Executive Officer, will participate in a corporate...

--Armata Pharmaceuticals, Inc., a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced a paper in the Journal of Molecular Biology, a peer-reviewed journal.

Armata Pharmaceuticals (ARMP) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Detailed price information for Palvella Therapeutics Inc (PVLA-Q) from The Globe and Mail including charting and trades.

ARMP stock jumps 10% as Armata Pharmaceuticals prepares its AP-SA02 multi-phage candidate for a pivotal Phase 3 trial in late 2026.

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced significant clinical, regulatory, manufacturing and operational progress supporting advancement of AP-SA02, the Company's intravenously administered Staphylococcus aureus ("S. aureus")